Next Article in Journal
Identification of Molecules from Coffee Silverskin That Suppresses Myostatin Activity and Improves Muscle Mass and Strength in Mice
Previous Article in Journal
Human Serum Albumin Labelling with a New BODIPY Dye Having a Large Stokes Shift
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 26
Issue 9
10.3390/molecules26092677
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Cocrystal of Apixaban–Quercetin: Improving Solubility and Bioavailability of Drug Combination of Two Poorly Soluble Drugs

by
Li Zhang
1,†,
Dewen Kong
2,†,
Hongjuan Wang
1,
Lingtai Jiao
1,
Xiaoyue Zhao
2,
Junke Song
2,
Dezhi Yang
1,
Haiguang Yang
2,
Shiying Yang
1,
Guanhua Du
2,* and
Yang Lu
1,*
1
Beijing City Key Laboratory of Polymorphic Drugs, Center of Pharmaceutical Polymorphs, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
2
Beijing City Key Laboratory of Drug Target and Screening Research, National Center for Pharmaceutical Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Molecules 2021, 26(9), 2677; https://doi.org/10.3390/molecules26092677
Submission received: 25 March 2021 / Revised: 27 April 2021 / Accepted: 28 April 2021 / Published: 3 May 2021
Browse Figures
Versions Notes

Abstract

:
Drug combinations have been the hotspot of the pharmaceutical industry, but the promising applications are limited by the unmet solubility and low bioavailability. In this work, novel cocrystals, consisting of two antithrombotic drugs with poor solubility and low bioavailability in vivo, namely, apixaban (Apx) and quercetin (Que), were developed to discover a potential method to improve the poor solubility and internal absorption of the drug combination. Compared with Apx, the dissolution behavior of Apx–Que (1:1) and Apx–Que–2ACN (1:1:2) was enhanced significantly, while the physical mixture of the chemicals failed to exhibit the advantages. The dissolution improvements of Apx–Que–2ACN could be explained by the fact that the solid dispersion-like structure and column-shaped cage of Que accelerated the access of the solvent to the inner layer of Apx. The fracture of the hydrogen bonds of Apx, which was the joint of the adjacent Que chains, facilitated the break-up of the structures. Besides, the bioavailability of Apx–Que was increased compared with the physical mixture and Apx, and Apx–Que remained stable in high temperature and illumination conditions. Therefore, a drug–drug cocrystal of two antithrombotic agents with poor solubility was developed, which exhibited greatly improved solubility, bioavailability and superior stability, indicating a novel method to overcome the shortages of drug combination.

Graphical Abstract

1. Introduction

Drug combination has attracted the expanding interests in pharmaceutical research in recent years. Compared with traditional drugs, drug combinations exhibit advantages in the increased patient compliance and adherence, the simplification of disease management, the reduced cost of drug products and the reduced probability of mono-therapy-induced resistant bacilli strains [1,2,3,4,5,6,7,8,9]. However, the promising applications of drug combinations are impeded by the limitations encountered in the formulation stages, such as poor solubility and stability, chemical interactions of ingredients, and decreased bioavailability.
Many approaches were conducted to improve the solubility and bioavailability of poorly soluble compounds of drug combination, for example, inclusion complex with hydroxypropyl-β-cyclodextrin (HP-β-CD), solid dispersion with highly water-soluble polymers, and micro-emulsion formulation [10,11,12,13,14,15]. Unfortunately, many of the methods are time consuming and limited by high cost. Besides, there are still more limitations including potential chemical interactions caused by introducing new materials into the formulation, and the high standard storage conditions required for the stability of the products.
Considering the practicability and atom-economic of the potential technique for industry application, drug–drug cocrystals could be an appropriate option to improve the solubility, bioavailability and pharmacological activity of target molecules, without modifying the chemical structure of drugs or introducing other materials into the formulation [16,17,18,19,20,21]. Moreover, the technique suited manufacture owing to the high efficiency, sustainability, and low cost. For example, Tramadol hydrochloride–celecoxib (a cocrystal drug for the treatment of pain) was approved by the China Food and Drug Administration (CFDA) in 2017 [22,23,24,25]. Herein, Apx–Que, a novel cocrystal of two anti-thrombotic agents, was designed based on the concept of cocrystal engineering.
Apixaban (Apx) (Scheme 1) is used to prevent venous thromboembolism (VTE) in hip or knee replacement surgery, and to decrease the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation [26,27,28,29]. Quercetin (Que) is a kind of flavonoid with an effect on reducing platelet aggregation in former studies [30,31,32,33,34,35]. Unfortunately, the potential superiority of the synergistic effect of the anticoagulant and anti-platelet drugs is restricted by the decreased solubility in physical combination as the agents are biopharmaceutical classification system (BCS) class II compounds. Therefore, cocrystal formation is adopted to improve the physicochemical properties of the drugs, and the first drug–drug cocrystal of Apx was presented, which may further improve its pharmacological activity.
The structures of apixaban–quercetin (Apx–Que) and apixaban–quercetin–2-acetonitrile (Apx–Que–2ACN) were characterized by single crystal X-ray diffraction (SXRD, Apx–Que–2ACN only), powder X-ray diffraction (PXRD), differential scanning calorimeter (DSC), and thermogravimetric analysis (TG). Compared with Apx, the solubility and bioavailability of Apx–Que were improved significantly, while the physical mixture of the chemicals failed to exhibit the advantages. The dissolution improvements of Apx–Que–2ACN could be explained by the fact that the solid dispersion-like structure and column-shaped cage of Que accelerated the access of the solvent to the inner layer of Apx, and the fracture of the hydrogen bonds of Apx, which was the joint of the adjacent Que chains, facilitated the break-up of the structures. Besides, Apx–Que exhibited excellent stability in high temperature and illumination conditions. Therefore, a drug–drug cocrystal of two antithrombotic agents with poor solubility was developed, which exhibited greatly improved solubility, bioavailability, and superior stability, indicating a novel method to overcome the shortages of drug combination.

2. Experimental Section

2.1. Materials

The solvents in analytical grade were purchased from Beijing Chemical Works. Apx and Que were purchased from Wuhan Yuancheng Technology Inc, with qualified purification (HPLC > 99%). Carbamazepine, which served as an internal standard (IS), was purchased from J&K Scientific (Beijing, China). Mass spectrometry grades of acetonitrile and methanol were obtained from J. T. Baker (J. T. Baker, Seattle, WA, USA). Formic acid was purchased from Thermo Fisher Scientific (Beijing China). All other chemicals used were of pharmaceutical grade.

2.2. Experimental Animals

Sprague Dawley (SD) rats (about 200 g, male, SPF grade) were purchased from Beijing Vital River Experimental Animal Co. Ltd. (Vital River, Beijing, China). Certificate no: SCXK (Beijing) 2016-0006. The animals were kept in an environment at 24 ± 2 °C with ad libitum access to food and water. Experimental protocols were performed in accordance with institutional guidelines for the care and use of laboratory animals at the Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College and the National Institutes of Health Guide for Care and Use of Laboratory Animals (publication no. 85-23, revised 1985).

2.3. Preparation of Apx–Que–2ACN

The powder sample was prepared by slurrying, and the single crystal was obtained with solution crystallization. Slurrying: a mixture of Apx (0.1 mmol, 46.0 mg) and Que (0.1 mmol, 30.2 mg) was added to 4 mL acetonitrile and ethyl acetate (1:1, v:v), and the suspension was stirred with IKA RT-10 at a rotation speed of 300 rpm for 3 h at 30 °C. After filtration, the solid was dried at 60 °C for 30 min. Solution crystallization: a mixture of Apx (0.1 mmol, 46.0 mg) and Que (0.1 mmol, 30.2 mg) was added to 50 mL acetonitrile and ethyl acetate (1:1, v:v). The suspension was heated to 60 °C, remaining for 15 min, and cooled down to room temperature. After filtration, the solution was crystallized at ambient temperature. A yellow plate-shaped crystal suitable for SXRD study was harvested after 30 days.

2.4. Preparation of Apx–Que

The powder sample was obtained from Apx–Que–2ACN, which was dried at 130 °C, 0.02 MPa with DZF-6020 (Shanghai Yiheng Technology Co., Ltd, Shanghai, China.) for 1 h and the solvent was removed completely.

2.5. SXRD

SXRD study of Apx–Que–2ACN was conducted at 293 K on a Rigaku MicroMax-002+ diffractometer (Rigaku, Tokyo, Japan) using CuKα radiation (λ = 1.54178 Å). The structure was solved by direct method and refined with full-matrix least-squares technique using OLEX2. Non-hydrogen atoms were refined with anisotropic displacement parameters. Hydrogen atoms were placed in calculated positions and refined with the riding model, and the protons on OH and NH were located from difference Fourier maps.

2.6. PXRD

Patterns of PXRD were obtained on a Rigaku D/max-2550 diffractometer (Rigaku, Tokyo, Japan) using CuKα radiation, and the voltage and current of the generator were set to 40 kV and 150 mA. Patterns were collected in the 2 θ range of 3–40° with a scan rate of 8° min−1 at ambient temperature, and the data were imaged, integrated and analyzed with Jade 6.

2.7. DSC

DSC was performed on Mettler Toledo DSC/DSC1 (Mettler Toledo, Zurich, Switzerland) equipment. The samples weighing 3–5 mg in a standard aluminum pan (40 μL) were heated from 30 °C to 300 °C at the rate of 10 °C min−1 under a nitrogen gas flow of 50 mL/min.

2.8. TGA

TGA analysis was performed on Mettler Toledo DSC/TGA1 (Mettler Toledo, Zurich, Switzerland) equipment with a flow of 50 mL/min of nitrogen as dry air. The samples were heated in the range of 30 °C to 500 °C at the rate of 10 °C min−1. The STAR software package (Mettler Toledo) was employed to record and analyze the TGA and DSC curves.

2.9. Stability Test

Approximately 50 mg Que–Apx in open containers was placed in the conditions of high temperature (60 ± 5 °C), high humidity (25 ± 5 °C, 90 ± 5%), and illumination (4500 ± 500 lx) for 10 days to investigate the stability via PXRD.

2.10. High Performance Liquid Chromatography (HPLC) Conditions

The concentration of samples in dissolution studies and intrinsic dissolution measurements were measured on an Agilent 1200 (Agilent, California, USA) with a diode array detector. The mobile phase was acetonitrile: 0.4% phosphoric acid = 30:70 (v:v), and a Kromasil 100-5-C18 column (Kromasil, Sweden) (250 mm × 4.6 mm, 5 um) was used as an analytic column; chromatograms were monitored at 254 nm and isocratic elution was used for all processes. The retention time of Apx and Que was 17.13 and 12.57 min, respectively.

2.11. Powder Dissolution Measurements

Powder dissolution measurements and intrinsic dissolution measurements were performed on an RC12AD (Tianjin TIANDA TIANFA pharmaceutical testing instrument manufacturer, Tianjin, China) with an automatic sampling system RZQ-12D (Tianjin TIANDA TIANFA pharmaceutical testing instrument manufacturer, Tianjin, China), where an equal volume of the blank dissolution media would be injected automatically into the dissolution vessels after sampling. The powder samples of Apx, physical mixture, Apx–Que, and Apx–Que–2ACN were milled at a rotation speed of about 60 rpm for 5 min with a agate mortar and pestle (Shanghai Lichen Bangxi Instrument Technology Co., Ltd., Shanghai, China), and sieved through 100-mesh sieves (Shaoxing Highway Instrument Equipment Co., Ltd.) in 2 min to minimize the size effect on results. Accurately weighed Apx (30.0 mg), physical mixture (49.7 mg), Apx–Que (49.7 mg), and Apx–Que–2ACN (55.2 mg), equivalent to 30.0 mg Apx, were added to dissolution vessels containing 450 mL media, namely, pure water, 0.1 M HCl, acetate buffer saline (ABS) of pH 4.5, and phosphate buffer saline (PBS) of pH 6.8. The suspensions were stirred at a rotation speed of 100 rpm at 37 °C, and sampled at 0, 5, 15, 30, 60, 90, 120, 180, 240, 360, and 480 min. The samplings were filtered through 0.22 μm PTFE filters, and the concentration of Apx was determined by HPLC. The remaining solids were filtrated and detected by PXRD, and the pH of the media after dissolution was also measured by pH Meter (Mettler Toledo, S210, Mettler Toledo, Zurich, Switzerland). The powder dissolution experiments were carried out in triplicate to evaluate the standard deviations.

2.12. Intrinsic Dissolution Measurements

Accurately weighed Apx (60.0 mg), physical mixture (99.4 mg), Apx–Que (99.4 mg), and Apx–Que–2ACN (110.4 mg), equivalent to 60.0 mg Apx, were compressed with a hydraulic press FODT-101Y (Shanghai Fukesi Analytical Instrument Co., Ltd., Shanghai, China) at 51.0 MPa (100 kg on a 0.196 cm2 disk) for 10 min to obtain a 5 mm diameter disk. One surface of the disk was sealed and the other one was exposed to the medium. The samples were added to dissolution vessels containing 450 mL pure water. The suspensions were stirred at a rotation speed of 100 rpm at 37 °C, and sampled at 0, 5, 10, 15, 20, 25, 30, 40, 50, and 60 min. The samplings were filtered through 0.22 μm PTFE filters, and the concentration of Apx was determined by HPLC. The IDR experiments were carried out in triplicate to evaluate the standard deviations.

2.13. Pharmacokinetic Study

2.13.1. Chromatographic Conditions

A high-performance liquid chromatography (Agilent 1260, Agilent, CA, USA) system equipped with an Agilent SB-C18 column (50 × 2.1 mm, 2.7 μm) was used for analysis. The mobile phase consisted of acetonitrile: water containing 0.1% formic acid = 50:50 (v/v) with a flow rate of 0.3 mL/min. The column temperature was set at 35 °C, and the elution time was 3 min. Within the ESI+ mode, protonated forms [M + H]+ at m/z 460.0 and 237.0 were chosen as precursor ions for apixaban and IS, with a fragment voltage of 160 V and 105 V, respectively.

2.13.2. Method Validation

The quantitative methods were validated with reference to the FDA guidelines on specificity, linearity, precision, accuracy, recovery, and stability compliance.
To ensure that endogenous and other substances in the sample would not interfere with the analysis of Apx and IS, the selectivity of the method was evaluated by comparing the blank rat plasma and corresponding spiked plasma chromatograms.
A calibration chart (n = 8) was constructed by plotting the peak area ratio of Apx to IS (y-axis) as a function of Apx (x-axis) concentration. Calculate the linear relationship of each standard curve by a weighted (1/x2) least squares linear regression and keep the concentration of the sample within the linear range.
The intra-day and inter-day accuracy and precision were determined by measuring three concentration levels (0.025, 0.6, 1.25 mg·L−1) of Apx in a single day and three consecutive days repeatedly. Accuracy and precision were defined as relative error (RE%) and percentage relative (RSD%), respectively, and the RE% is expected to be within 15%.
Comparing the peak area of the analyte in extracted samples with the corresponding untreated standard solution, the absolute recovery was measured. Finally, the stability of quality control samples (QCs) in biological samples was assessed in different storage conditions, including at 25 °C for 24 h and three freeze–thaw at −80 °C cycles.

2.13.3. Pharmacokinetics

Apx, physical mixture, and Apx–Que were orally administered at the dosage of 60 mg·kg−1 (the equivalent amount of free apixaban for cocrystal) in rats. Blood samples were collected from the ocular vein into heparinized tubes at the following time intervals: 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h after administration. The samples were centrifuged at 6000 rpm (10 min, 4 °C), and the supernatants of samples were stored at −80 °C until analysis. Plasma (100 μL) was mixed with 10 μL solution of carbamazepine (1 mg·L−1, used as the internal standard, IS) and 290 μL of acetonitrile. After centrifugation (10 min, 1340 rpm), 10 μL of supernatant was injected into the LC-MS for analysis. The drug concentration data of Apx in the plasma were completed by DAS 2.0 software and were expressed as the mean ± standard deviation (mean ± SD).

3. Results and Discussion

3.1. Crystal Structure Analysis

The structure was solved by the direct method and refined with the full-matrix least-squares technique using OLEX2. Non-hydrogen atoms were refined with anisotropic displacement parameters. Hydrogen atoms were placed in calculated positions and refined with the riding model, and the protons on OH and NH were located from difference Fourier maps. Apx–Que–2ACN was crystallized in the monoclinic space group P21/n with one Apx, one Que, and two acetonitrile molecules in its asymmetric unit (Figure 1a). Crystallographic data are summarized in Table 1. The adjacent Que molecules were joined through O8-H8A···O10 (2.786 Å), generating a 1-D chain structure (Figure 1b) along the b axis, and an intramolecular hydrogen bond O6-H6···O7 (2.648 Å) was formed in Que (Table 2).
Apx was connected to two Que molecules via hydrogen bonds and filled in the voids among Que chains. Apx and the first Que were connected with hydrogen bonds O11-H11A···N4 (2.878 Å) and N5-H5B···O11 (3.180 Å) of motif R 2 2 ( 7 ) , and linked the second Que with O5-H5···O3 (2.698 Å) and O10-H10A···O1 (2.615 Å). The hydrogen bonds were formed owing to the similar size of the two molecules, so that the distance between the carbonyl groups (hydrogen donors) of Apx and hydroxyl groups (hydrogen receptors) of Que was suitable to form a pair of hydrogen bonds. An acetonitrile molecule was related to Apx by N5-H5A···N6 (3.053 Å). Interestingly, no hydrogen bond was found among Apx molecules, and the structure was similar to solid dispersion so that the chains of Que could be regarded as a carrier, which Apx was attached to (Figure 1c). In addition, two Apx were captured by six Que molecules with a column-shaped cage, which formed a channel along a axis owing to the layer structure (Figure 2).

3.2. PXRD Analysis

Powder samples of Apx–Que–2ACN and Apx–Que were studied by PXRD to confirm the formation of the cocrystals. The patterns of Apx–Que–2ACN and Apx–Que are shown in Figure 3.
The PXRD results showed that there were diffraction peaks at 2θ values of 8.54, 11.32, 12.98, 14.04, 17.08, 18.52, 21.36, and 22.38° in Apx, and 6.36, 10.90, 12.59, 15.06, 15.32, 18.04, and 24.12° in Que. Diffraction peaks at 2θ values of 6.36, 8.54, 10.90, 12.59, 14.04, 17.08, 18.52, 22.38, and 27.30° could be found in the physical mixture of Apx and Que. New diffraction peaks at 2θ values of 6.82, 6.92, 10.30, 12.98, 13.84, 15.32, 15.92, 16.36, 20.50, 22.72, 23.64, 25.48, 28.10, and 29.42° were shown in Apx–Que, while the characteristic peaks of Apx and Que disappeared. The experimental profile of Apx–Que–2ACN was in good agreement with the simulated ones, indicating the high purity of the powder sample. Completely new diffraction peaks at 2θ values of 6.76, 7.00, 9.64, 10.34, 14.42, 15.32, 16.30, 16.72, 23.32, and 27.08° were present in Apx–Que–2ACN. The experimental patterns of Apx–Que and Apx–Que–2ACN differed from the original and other reported crystal forms of single components (Figure 4).

3.3. Thermal Analysis

The DSC results (Figure 5) showed that the endothermic peak of Apx was at 237.51 °C [36], and endothermic peaks of crystal water and the melting point of Que were at about 122.44 and 317.60 °C [37], respectively. The endothermic peaks of the physical mixture were at about 118.95, 200.94 and 225.82 °C. There were studies about the salt solvate and cocrystal solvate that the endothermic peak of acetonitrile verified from 83 °C to 148 °C [38,39]. The endothermic peaks of acetonitrile and the melting of Apx–Que–2ACN, the PXRD pattern of which was in good agreement with the simulated ones, were at 142.34 and 151.05 °C, respectively, where part of the two endothermic peaks overlapped. DSC measurements confirmed the cocrystal formation of Apx–Que through a sharp endothermic peak at 142.34 °C, which indicated that the physicochemical properties of Apx–Que differed from the original chemicals and the physical mixture. TG analysis [40,41,42,43,44,45] was conducted to ensure the content of ACN in Apx–Que–2ACN was consistent with the SCXRD result that two acetonitrile molecules were included in its asymmetric unit. The weight loss in the TGA pattern of Apx–Que–2ACN was 9.45%, equivalent to 1.94 acetonitrile molecules, which was in good agreement with the SCXRD result. Apx–Que was prepared by heating Apx–Que–2ACN at 130 °c, 0.02 MPa for 1 h, and the TG experiment (Figure 6) was performed to ensure acetonitrile was removed completely. No weight loss observed in the TG analysis of Apx–Que indicated Apx–Que–2ACN was transformed into Apx–Que thoroughly.

3.4. Stability Analysis

The stability of Apx–Que in extreme conditions was studied and the results are shown in Figure 7. The powder samples in high temperature and illumination conditions remained stable after 10 days, but not stable in high humidity conditions, which illustrated that the products needed dry storage at room temperature.

3.5. Powder Dissolution Measurements and IDR Studies

Improving the dissolution behavior of drugs is important to expand the applications of drug combination, as improved apparent solubility can result in enhanced bioavailability. The solubility of Apx–Que–2ACN and Apx–Que was significantly improved in dissolution media compared with pure Apx, while the mixture decreased vastly. The measurements are presented in Figure 8. The maximum concentration of the physical mixture decreased 14% in pure water, 78% in 0.1 M HCl, 57% in ABS, and 52% in PBS. Meanwhile, the maximum concentration of Apx–Que–2ACN was approximately 1.3 times higher than Apx in pure water, 1.8 times in 0.1 M HCl, and 2.4 times in PBS, and Apx–Que was approximately 1.7 times higher than Apx in pure water, 2.0 times in 0.1 M HCl, and 2.4 times in PBS. The enhanced dissolution behavior of the cocrystals lasted for more than 8 h, which could lead to improved bioavailability.
The formation of samples after dissolution studies was examined through PXRD, which showed that Apx and the physical mixture were stable in dissolution media during the solubility study, but Apx–Que and Apx–Que–2ACN were transformed into the mixture of Apx (Form H2) and Que in the process (Figure 9). The pH of the media after dissolution studies is summarized in Table 3.
It is known that IDR is with a better correlation in in vivo drug dissolution dynamics than powder solubility. In order to obtain quantitative information of the dissolution rates, IDR experiments for the samples were performed and the curves of cocrystals were substantially different from Apx (Figure 10). The result showed that the dissolution rate of Apx in physical mixture did not exhibit advantage. However, the release of Apx in Apx–Que–2ACN and Apx–Que was about 6 and 8 times higher than pure Apx, respectively, which indicated the probability of cocrystals to improve the absorption and bioavailability.
The results indicated that the solubility of Apx was not improved in the formation of physical mixture owing to the poor solubility of Que in water that insoluble Que attached to Apx and decreased the contact area of water and Apx, which resulted in a decreased dissolution rate. However, the dissolution behavior of the cocrystals was improved significantly in the dissolution studies, which could be explained by the fact that the permutations in cocrystals differed from the original components. In Apx–Que–2ACN, Apx was captured by Que molecules and attached to the chains with hydrogen bonds, which formed a solid-dispersion structure and changed the hydrogen bonds among Apx and Que molecules. Moreover, the column-shaped cage generated a channel which helped the access of the media to inner layer Apx molecules. Besides, Apx was the joint of the adjacent Que chains and the fracture of the hydrogen bonds during the dissolution accelerated the breakup of the structure. When an Apx molecule was dissolved, the neighboring Apx would be exposed to the media fully, which facilitated the dissolution.
It is an interesting phenomenon in the dissolution studies that the physical mixture was not significantly different with the pure drug in water, but the two profiles are completely different in acetate buffer, 0.1 M hydrochloric acid, and phosphate buffer. There were studies showing that the solubility of the drug could be influenced by the different buffers and pH of the media [46,47]. Balvant Yadav [48] found that the solubility of isoniazid differed from the physical mixture and the cocrystal of isoniazid and quercetin in water, acetate buffer, 0.1 M hydrochloric acid, and phosphate buffer. Shuzhen Ren [49] found that the pH of the media influenced the solubility of pure components and cocrystals. In our studies, the pH of the water after dissolution studies (Table 3) of Apx and the physical mixture was 6.5 and 6.1, respectively, which indicated that the media environment of the physical mixture was different compared with that of pure Apx. Meanwhile, the pH of the other three buffers after dissolution studies was not changed compared with the original ones, which may lead to the different result in pure water compared with the other three buffers. Moreover, the irons in the four media were different, and the properties may influence the solubility of the pure component, physical mixture and cocrystals that the dissolution results of samples in four media were significantly different.

3.6. Pharmacokinetic Study

3.6.1. Method Validation

The separation time of Apx and IS was 1.4 and 1.6 min, respectively. The peak shape was presented well with acceptable baseline noise and selectivity. No interference of endogenous or other substances was detected (Figure 11).
The calibration curve displayed good linearity (R2 = 0.9995) within the concentration range of 0.01–1.5 mg·L−1 for Apx, and the regression equation of the plot was y = 0.004 x − 0.02. The intra-day and inter-day accuracy (RE %) ranged from −0.64 to 4.49%, and the precision (RSD %) was lower than 5.94%.
The recovery is used to evaluate the ability to extract analytes from biological samples. In this study, the recoveries of Apx at three concentrations were (108.48 ± 0.76) %, (105.32 ± 38.31) % and (102.20 ± 49.98) %, with an RSD of 2.82%, 6.06% and 3.91%, respectively. Under different storage conditions, Apx has an RE range of 12.32% to 4.93% and an RSD of 0.18% to 4.65%, indicating that the developed method was reliable and reusable for quantitative analysis.

3.6.2. Pharmacokinetic Analysis

Pharmacokinetics in male rats was performed to evaluate the bioavailability improvement of the cocrystal. The plasma concentration after oral administration was measured. The plasma concentration–time profiles of Apx, the physical mixture, and Apx–Que are shown in Figure 12, and the mean pharmacokinetic parameters are summarized in Table 4. The plasma concentration of Apx–Que was improved significantly compared with Apx and the physical mixture. The Cmax and AUC0-t of Apx–Que increased 28.89 and 31.24 times compared with Apx, while those of the physical mixture decreased to 0.68 and 0.42 times. The result could be explained by the different dissolution behavior of the materials and that the enhanced solubility of Apx–Que accelerated the absorption and the physical mixture failed to improve the bioavailability because of its decreased dissolution, indicating that different formations influenced the pharmacokinetics of the chemicals and cocrystals could be adopted to improve the oral bioavailability of Apx. Moreover, the Tmax of Apx–Que delayed, and the enhanced plasma concentration of Apx–Que lasted over 24 h. Notably, the clearance of Apx–Que decreased significantly compared to Apx and the physical mixture, which may also be one of the important reasons for its high Apx concentration.

4. Conclusions

Herein, we developed Apx–Que, a drug-drug cocrystal of antithrombotic agents with poor solubility, providing an alternative method for the innovative modification of drug combinations, with the probability to improve the safety and efficacy compared with pure Apx. Compared with Apx, the dissolution behavior of Apx–Que and Apx–Que–2ACN was enhanced significantly and the bioavailability of Apx–Que was increased compared with Apx, which illustrated that it was meaningful to study drug–drug cocrystals for pharmaceutical development. The improvements of Apx–Que–2ACN could be explained by the fact that the solid dispersion-like structure and column-shaped cage of Que accelerated the access of the solvent to the inner layer of Apx, and the fracture of hydrogen bonds of Apx, which was the joint of the adjacent Que chains, facilitated the break-up of the structure. Besides, Apx–Que exhibited excellent stability in high temperature and illumination conditions. Considering the practicability and atom-economic of the potential technique for industry application, the method suits manufacture owing to the high efficiency, sustainability, stability, and low cost, and it can be concluded that the drug–drug cocrystal is a promising approach to expand the applications of drug combinations without modifying the chemical structures of drugs or introducing other materials in the formulation.

Author Contributions

Study design, L.Z.; Writing, D.K.; Data analysis, H.W.; Literature search, L.J.; Data collection, X.Z.; Figure, J.S.; Data analysis, D.Y.; Data analysis, H.Y.; Data analysis, S.Y.; Data analysis, G.D.; Data analysis, Y.L. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by National Key R&D Program of China (2016YFC1000900), CAMS Innovation Fund for Medical Sciences (2017-I2M-1-010), and National Science and Technology Major Project of China (2020-I2M-1-003).

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of NAME OF INSTITUTE (protocol codeD0005408).

Informed Consent Statement

Not applicable.

Data Availability Statement

Date of the compounds are available from the authors.

Competing Financial Interests:

The authors declare no competing financial interests.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the compounds are available from the authors.

References

  1. Fleig, S.V.; Weger, B.; Haller, H.; Limbourg, F.P. Effectiveness of a Fixed-Dose, Single-Pill Combination of Perindopril and Amlodipine in Patients with Hypertension: A Non-Interventional Study. Adv. Ther. 2018, 35, 353–366. [Google Scholar] [CrossRef] [Green Version]
  2. Bakris, G.L.; A Sarafidis, P.; Weir, M.R.; Dahlöf, B.; Pitt, B.; Jamerson, K.; Velazquez, E.J.; Staikos-Byrne, L.; Kelly, R.Y.; Shi, V.; et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): A prespecified secondary analysis of a randomised controlled trial. Lancet 2010, 375, 1173–1181. [Google Scholar] [CrossRef]
  3. Egan, C.G.; Pontremoli, R. Role of the fixed-dose combination lercanidipine-enalapril in renal protection. J. Nephrol. 2011, 24, 428–437. [Google Scholar] [CrossRef]
  4. German, P.; Mathias, A.; Brainard, D.M.; Kearney, B.P. Drug–Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir/Sofosbuvir. Clin. Pharmacokinet. 2018, 57, 1369–1383. [Google Scholar] [CrossRef] [PubMed]
  5. Giles, T.D.; A Weber, M.; Basile, J.; Gradman, A.H.; Bharucha, D.B.; Chen, W.; Pattathil, M. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: A randomised, multicentre study. Lancet 2014, 383, 1889–1898. [Google Scholar] [CrossRef]
  6. Hair, P.I.; Scott, L.J.; Perry, C.M. Fixed-dose combination lercanidipine/enalapril. Drugs 2007, 67, 95–106. [Google Scholar] [CrossRef]
  7. Lawitz, E.; Poordad, F.F.; Pang, P.S.; Hyland, R.H.; Ding, X.; Mo, H.; Symonds, W.T.; McHutchison, J.G.; E Membreno, F. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial. Lancet 2014, 383, 515–523. [Google Scholar] [CrossRef]
  8. Poordad, F.; Sievert, W.; Mollison, L.; Bennett, M.; Tse, E.; Bräu, N.; Levin, J.; Sepe, T.; Lee, S.S.; Angus, V.; et al. Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection. JAMA 2015, 313, 1728–1735. [Google Scholar] [CrossRef] [PubMed]
  9. Tshefu, A.K.; Gaye, O.; Kayentao, K.; Thompson, R.; Bhatt, K.M.; Sesay, S.S.S.; Bustos, D.G.; Tjitra, E.; Bedu-Addo, G.; Borghini-Fuhrer, I.; et al. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: A randomised non-inferiority trial. Lancet 2010, 375, 1457–1467. [Google Scholar] [CrossRef]
  10. Figueirêdo, C.B.M.; Nadvorny, D.; Vieira, A.C.Q.D.M.; Schver, G.C.R.D.M.; Sobrinho, J.L.S.; Neto, P.J.R.; Lee, P.I.; Soares, M.F.D.L.R. Enhanced delivery of fixed-dose combination of synergistic antichagasic agents posaconazole-benznidazole based on amorphous solid dispersions. Eur. J. Pharm. Sci. 2018, 119, 208–218. [Google Scholar] [CrossRef] [PubMed]
  11. Glass, S.A.-K.A.M.H.W.B.D.; Agatonovic-Kustrin, S.; Wisch, M.H. Artificial Neural Networks to Optimize Formulation Components of a Fixed- Dose Combination of Rifampicin, Isoniazid and Pyrazinamide in a Microemulsion. Curr. Drug Discov. Technol. 2005, 2, 195–201. [Google Scholar] [CrossRef]
  12. Mitra, A.; Wu, Y. Challenges and Opportunities in Achieving Bioequivalence for Fixed-Dose Combination Products. AAPS J. 2012, 14, 646–655. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Shishoo, C.J.; A Shah, S.; Rathod, I.S.; Savale, S.S.; Vora, M.J. Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation. Int. J. Pharm. 2001, 228, 53–67. [Google Scholar] [CrossRef]
  14. Singh, S.; Mariappan, T.; Shankar, R.; Sarda, N.; Singh, B. A critical review of the probable reasons for the poor variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem. Int. J. Pharm. 2001, 228, 5–17. [Google Scholar] [CrossRef]
  15. Taupitz, T.; Dressman, J.B.; Klein, S. New formulation approaches to improve solubility and drug release from fixed dose combinations: Case examples pioglitazone/glimepiride and ezetimibe/simvastatin. Eur. J. Pharm. Biopharm. 2013, 84, 208–218. [Google Scholar] [CrossRef]
  16. Bethune, S.J.; Huang, N.; Jayasankar, A.; Rodríguez-Hornedo, N. Understanding and Predicting the Effect of Cocrystal Components and pH on Cocrystal Solubility. Cryst. Growth Des. 2009, 9, 3976–3988. [Google Scholar] [CrossRef]
  17. Friščić, T.; Childs, S.L.; Rizvi, S.A.A.; Jones, W. The role of solvent in mechanochemical and sonochemical cocrystal formation: A solubility-based approach for predicting cocrystallisation outcome. CrystEngComm 2008, 11, 418–426. [Google Scholar] [CrossRef]
  18. Li, Z.; Li, M.; Peng, B.; Zhu, B.; Wang, J.-R.; Mei, X. Improving Compliance and Decreasing Drug Accumulation of Diethylstilbestrol through Cocrystallization. Cryst. Growth Des. 2019, 19, 1942–1953. [Google Scholar] [CrossRef]
  19. Nicoli, S.; Bilzi, S.; Santi, P.; Caira, M.; Li, J.; Bettini, R. Ethyl-paraben and nicotinamide mixtures: Apparent solubility, thermal behavior and X-ray structure of the 1:1 co-crystal. J. Pharm. Sci. 2008, 97, 4830–4839. [Google Scholar] [CrossRef] [PubMed]
  20. Putra, O.D.; Furuishi, T.; Yonemochi, E.; Terada, K.; Uekusa, H. Drug–Drug Multicomponent Crystals as an Effective Technique to Overcome Weaknesses in Parent Drugs. Cryst. Growth Des. 2016, 16, 3577–3581. [Google Scholar] [CrossRef]
  21. Sa, R.; Zhang, Y.; Deng, Y.; Huang, Y.; Zhang, M.; Lou, B. Novel Salt Cocrystal of Chrysin with Berberine: Preparation, Characterization, and Oral Bioavailability. Cryst. Growth Des. 2018, 18, 4724–4730. [Google Scholar] [CrossRef]
  22. Almansa, C.; Mercè, R.; Tesson, N.; Farran, J.; Tomàs, J.; Plata-Salamán, C.R. Co-crystal of Tramadol Hydrochloride–Celecoxib (ctc): A Novel API–API Co-crystal for the Treatment of Pain. Cryst. Growth Des. 2017, 17, 1884–1892. [Google Scholar] [CrossRef]
  23. López-Cedrún, J.; Videla, S.; Burgueño, M.; Juárez, I.; Aboul-Hosn, S.; Martin-Granizo, R.; Grau, J.; Puche, M.; Gil-Diez, J.-L.; Hueto, J.-A.; et al. Co-crystal of Tramadol-Celecoxib in Patients with Moderate to Severe Acute Post-surgical Oral Pain: A Dose-Finding, Randomised, Double-Blind, Placebo- and Active-Controlled, Multicentre, Phase II Trial. Drugs R&D 2018, 18, 137–148. [Google Scholar] [CrossRef] [Green Version]
  24. Port, A.; Almansa, C.; Enrech, R.; Bordas, M.; Plata-Salamán, C.R. Differential Solution Behavior of the New API–API Co-Crystal of Tramadol–Celecoxib (CTC) versus Its Constituents and Their Combination. Cryst. Growth Des. 2019, 19, 3172–3182. [Google Scholar] [CrossRef] [Green Version]
  25. Videla, S.; Lahjou, M.; Vaqué, A.; Sust, M.; Escriche, M.; Soler, L.; Sans, A.; Sicard, E.; Gascón, N.; Encina, G.; et al. Pharmacokinetics of multiple doses of co-crystal of tramadol-celecoxib: Findings from a four-way randomized open-label phase I clinical trial. Br. J. Clin. Pharmacol. 2018, 84, 64–78. [Google Scholar] [CrossRef]
  26. Agnelli, G.; Buller, H.R.; Cohen, A.; Curto, M.; Gallus, A.S.; Johnson, M.; Porcari, A.; Raskob, G.E.; Weitz, J.I. Apixaban for extended treatment of venous thromboembolism. New Engl. J. Med. 2013, 368, 699–708. [Google Scholar] [CrossRef]
  27. Alexander, J.H.; Lopes, R.D.; James, S.; Kilaru, R.; He, Y.; Mohan, P.; Bhatt, D.L.; Goodman, S.; Verheugt, F.W.; Flather, M.; et al. Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. New Engl. J. Med. 2011, 365, 699–708. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Raghavan, N.; Frost, C.E.; Yu, Z.; He, K.; Zhang, H.; Humphreys, W.G.; Pinto, D.; Chen, S.; Bonacorsi, S.; Wong, P.C.; et al. Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans. Drug Metab. Dispos. 2008, 37, 74–81. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  29. Wong, P.C.; Crain, E.J.; Xin, B.; Wexler, R.R.; Lam, P.Y.S.; Pinto, D.J.; Luettgen, J.M.; Knabb, R.M. Apixaban, an oral, direct and highly selective factor Xa inhibitor:in vitro, antithrombotic and antihemostatic studies. J. Thromb. Haemost. 2008, 6, 820–829. [Google Scholar] [CrossRef]
  30. Beretz, A.; Cazenave, J.-P.; Anton, R. Inhibition of aggregation and secretion of human platelets by quercetin and other flavonoids: Structure-activity relationships. Inflamm. Res. 1982, 12, 382–387. [Google Scholar] [CrossRef]
  31. Beretz, A.; Stierle, A.; Anton, R.; Cazenave, J.-P. Role of cyclic AMP in the inhibition of human platelet aggregation by quercetin, a flavonoid that potentiates the effect of prostacyclin. Biochem. Pharmacol. 1982, 31, 3597–3600. [Google Scholar] [CrossRef]
  32. Duan, Y.; Sun, N.; Xue, M.; Wang, X.; Yang, H. Synthesis of regioselectively acylated quercetin analogues with improved antiplatelet activity. Mol. Med. Rep. 2017, 16, 9735–9740. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Hubbard, G.P.; Wolffram, S.; De Vos, R.; Bovy, A.; Gibbins, J.M.; A Lovegrove, J. Ingestion of onion soup high in quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in man: A pilot study. Br. J. Nutr. 2006, 96, 482–488. [Google Scholar] [PubMed]
  34. Kobzar, G.; Mardla, V.; Samel, N. Effects of α-tocopherol, l-arginine, and quercetin on aggregation of human platelets. Nutr. Res. 2005, 25, 569–575. [Google Scholar] [CrossRef]
  35. Oh, W.J.; Endale, M.; Park, S.-C.; Cho, J.Y.; Rhee, M.H. Dual Roles of Quercetin in Platelets: Phosphoinositide-3-Kinase and MAP Kinases Inhibition, and cAMP-Dependent Vasodilator-Stimulated Phosphoprotein Stimulation. Evidence-Based Complement. Altern. Med. 2012, 2012, 1–10. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Chen, Y.; Li, L.; Yao, J.; Ma, Y.-Y.; Chen, J.-M.; Lu, T.-B. Improving the Solubility and Bioavailability of Apixaban via Apixaban–Oxalic Acid Cocrystal. Cryst. Growth Des. 2016, 16, 2923–2930. [Google Scholar] [CrossRef]
  37. Liu, F.; Wang, L.-Y.; Yu, M.-C.; Li, Y.-T.; Wu, Z.-Y.; Yan, C.-W. A new cocrystal of isoniazid-quercetin with hepatoprotective effect: The design, structure, and in vitro/in vivo performance evaluation. Eur. J. Pharm. Sci. 2020, 144, 105216. [Google Scholar] [CrossRef] [PubMed]
  38. Jiao, L.-T.; Yang, D.-Z.; Zhang, L.; Yang, S.-Y.; Du, G.-H.; Lu, Y. Salt solvates of quinolones and oxicams: Theoretical computation, structural characterization and dissolution studies. J. Mol. Struct. 2021, 1223, 128865. [Google Scholar] [CrossRef]
  39. Liu, X.; Michalchuk, A.A.L.; Pulham, C.R.; Boldyreva, E.V. An acetonitrile-solvated cocrystal of piroxicam and succinic acid with co-existing zwitterionic and non-ionized piroxicam molecules. Acta Crystallogr. Sect. C Struct. Chem. 2019, 75, 29–37. [Google Scholar] [CrossRef] [PubMed]
  40. Chen, S.; Cheng, Y.; Xie, Q.; Xiao, B.; Wang, Z.; Liu, J.; Wu, G. Enhanced breakdown strength of aligned-sodium-titanate- nanowire/epoxy nanocomposites and their anisotropic dielectric properties. Compos. Part. A: Appl. Sci. Manuf. 2019, 120, 84–94. [Google Scholar] [CrossRef]
  41. Chen, S.; Meng, G.; Kong, B.; Xiao, B.; Wang, Z.; Jing, Z.; Gao, Y.; Wu, G.; Wang, H.; Cheng, Y. Asymmetric alicyclic amine-polyether amine molecular chain structure for improved energy storage density of high-temperature crosslinked polymer capacitor. Chem. Eng. J. 2020, 387, 123662. [Google Scholar] [CrossRef]
  42. Cui, J.; Zhou, Z.; Jia, M.; Chen, X.; Shi, C.; Zhao, N.; Guo, X. Solid Polymer Electrolytes with Flexible Framework of SiO2 Nanofibers for Highly Safe Solid Lithium Batteries. Polymers 2020, 12, 1324. [Google Scholar] [CrossRef]
  43. Pan, C.; Kou, K.; Zhang, Y.; Li, Z.; Wu, G. Enhanced through-plane thermal conductivity of PTFE composites with hybrid fillers of hexagonal boron nitride platelets and aluminum nitride particles. Compos. Part. B: Eng. 2018, 153, 1–8. [Google Scholar] [CrossRef]
  44. Pan, C.; Zhang, J.; Kou, K.; Zhang, Y.; Wu, G. Investigation of the through-plane thermal conductivity of polymer composites with in-plane oriented hexagonal boron nitride. Int. J. Heat Mass Transf. 2018, 120, 1–8. [Google Scholar] [CrossRef]
  45. Wan, L.; Zhang, X.; Wu, G.; Feng, A. Thermal conductivity and dielectric properties of bismaleimide/cyanate ester copolymer. High. Volt. 2017, 2, 167–171. [Google Scholar] [CrossRef]
  46. Machado, T.C.; Kuminek, G.; Cardoso, S.G.; Rodríguez-Hornedo, N. The role of pH and dose/solubility ratio on cocrystal dissolution, drug supersaturation and precipitation. Eur. J. Pharm. Sci. 2020, 152, 105422. [Google Scholar] [CrossRef]
  47. Shimpi, M.R.; Alhayali, A.; Cavanagh, K.L.; Rodríguez-Hornedo, N.; Velaga, S.P.J.C.G. Tadalafil–malonic acid cocrystal: Physicochemical characterization, pH-solubility, and supersaturation studies. Cryst. Growth Des. 2018, 18, 4378–4387. [Google Scholar]
  48. Yadav, B.; Gunnam, A.; Thipparaboina, R.; Nangia, A.K.; Shastri, N.R. Hepatoprotective Cocrystals of Isoniazid: Synthesis, Solid State Characterization, and Hepatotoxicity Studies. Cryst. Growth Des. 2019, 19, 5161–5172. [Google Scholar] [CrossRef]
  49. Ren, S.; Liu, M.; Hong, C.; Li, G.; Sun, J.; Wang, J.; Zhang, L.; Xie, Y. The effects of pH, surfactant, ion concentration, coformer, and molecular arrangement on the solubility behavior of myricetin cocrystals. Acta Pharm. Sin. B 2019, 9, 59–73. [Google Scholar] [CrossRef] [PubMed]
Molecules 26 02677 sch001 550
Scheme 1. Chemical structures of apixaban (A) and quercetin (B).
Scheme 1. Chemical structures of apixaban (A) and quercetin (B).
Molecules 26 02677 sch001
Molecules 26 02677 g001 550
Figure 1. Crystal structure of Apx–Que–2ACN. (a) Asymmetric unit and hydrogen bonds of Apx–Que–2ACN. (b) Chain structure of Que. (c) Crystal packing network.
Figure 1. Crystal structure of Apx–Que–2ACN. (a) Asymmetric unit and hydrogen bonds of Apx–Que–2ACN. (b) Chain structure of Que. (c) Crystal packing network.
Molecules 26 02677 g001
Molecules 26 02677 g002 550
Figure 2. Column-shaped cage in Apx–Que–2ACN. (a) Que cage. (b) Channel along a axis.
Figure 2. Column-shaped cage in Apx–Que–2ACN. (a) Que cage. (b) Channel along a axis.
Molecules 26 02677 g002
Molecules 26 02677 g003 550
Figure 3. PXRD pattern of (a) experimental Apx–Que, (b) simulated Apx–Que–2ACN, (c) experimental Apx–Que–2ACN, (d) physical mixture, (e) Apx, and (f) Que.
Figure 3. PXRD pattern of (a) experimental Apx–Que, (b) simulated Apx–Que–2ACN, (c) experimental Apx–Que–2ACN, (d) physical mixture, (e) Apx, and (f) Que.
Molecules 26 02677 g003
Molecules 26 02677 g004 550
Figure 4. Original and other reported crystal forms of Apx and Que. (a) Form H2 and (b) N-1 of Apx, (c) Form I of Que, (d) Que hydrate, and(e) Que dihydrate.
Figure 4. Original and other reported crystal forms of Apx and Que. (a) Form H2 and (b) N-1 of Apx, (c) Form I of Que, (d) Que hydrate, and(e) Que dihydrate.
Molecules 26 02677 g004
Molecules 26 02677 g005 550
Figure 5. The DSC patterns of (a) Apx, (b) Que, (c) physical mixture of Apx and Que, (d) Apx–Que–2ACN, and (e) Apx–Que.
Figure 5. The DSC patterns of (a) Apx, (b) Que, (c) physical mixture of Apx and Que, (d) Apx–Que–2ACN, and (e) Apx–Que.
Molecules 26 02677 g005
Molecules 26 02677 g006 550
Figure 6. The TGA patterns of (a) Apx–Que–2ACN and (b) Apx–Que.
Figure 6. The TGA patterns of (a) Apx–Que–2ACN and (b) Apx–Que.
Molecules 26 02677 g006
Molecules 26 02677 g007 550
Figure 7. The PXRD patterns of stability studies of Apx–Que. (a) High temperature, (b) illumination, (c) high humidity, and (d) original Apx–Que.
Figure 7. The PXRD patterns of stability studies of Apx–Que. (a) High temperature, (b) illumination, (c) high humidity, and (d) original Apx–Que.
Molecules 26 02677 g007
Molecules 26 02677 g008 550
Figure 8. Powder dissolution profiles of Apx, physical mixture, Apx–Que–2ACN, and Apx–Que.
Figure 8. Powder dissolution profiles of Apx, physical mixture, Apx–Que–2ACN, and Apx–Que.
Molecules 26 02677 g008
Molecules 26 02677 g009 550
Figure 9. PXRD patterns of samples before and after dissolution. Green lines for Apx, blue lines for physical mixture, red lines for Apx–Que–2ACN, and pink lines for Apx–Que.
Figure 9. PXRD patterns of samples before and after dissolution. Green lines for Apx, blue lines for physical mixture, red lines for Apx–Que–2ACN, and pink lines for Apx–Que.
Molecules 26 02677 g009
Molecules 26 02677 g010 550
Figure 10. IDR profiles of Apx, physical mixture, Apx–Que–2ACN, and Apx–Que.
Figure 10. IDR profiles of Apx, physical mixture, Apx–Que–2ACN, and Apx–Que.
Molecules 26 02677 g010
Molecules 26 02677 g011 550
Figure 11. LC-MS chromatograms of Apx (left) and IS (right) obtained by deproteinization of (a) blank plasma, (b) blank plasma spiked with Apx and IS, (c) plasma sample after oral administration of Apx spiked with IS.
Figure 11. LC-MS chromatograms of Apx (left) and IS (right) obtained by deproteinization of (a) blank plasma, (b) blank plasma spiked with Apx and IS, (c) plasma sample after oral administration of Apx spiked with IS.
Molecules 26 02677 g011
Molecules 26 02677 g012 550
Figure 12. Mean plasma concentration–time curves of oral Apx, physical mixture, and Apx–Que in SD rats (x ± s, n = 5).
Figure 12. Mean plasma concentration–time curves of oral Apx, physical mixture, and Apx–Que in SD rats (x ± s, n = 5).
Molecules 26 02677 g012
Table
Table 1. Crystallographic data of Apx–Que–2ACN.
Table 1. Crystallographic data of Apx–Que–2ACN.
CompoundApx–Que–2ACN
Empirical formulaC44H41N7O11
T (K)293
Crystal systemmonoclinic
Space groupP21/n
a (Å)17.115
b (Å)12.888
c (Å)19.500
α (deg)90.00
β (deg)92.06
γ (deg)90.00
Volume (Å3)4298
Z4
Calculated density (g/cm3)1.304
Absorption coeff. (mm−1)0.794
F (000)1768
Crystal size (mm)0.2×0.2×0.2
Rint0.0710
R1 [I>2σ(I)]0.0712
wR2 (all data)0.2170
GOF1.087
Table
Table 2. Hydrogen bonds of Apx–Que–2ACN.
Table 2. Hydrogen bonds of Apx–Que–2ACN.
D-H···Ad (D···A) (Å)∠ (DHA) (deg)Symmetry Code
N5-H5A···N63.053172.33[-x+1, -y, -z+1]
N5-H5B···O113.180165.31[x+1/2, -y+1/2, z+1/2]
O5-H5···O32.698173.81[x, y+1, z]
O6-H6···O72.648148.68
O8-H8A···O102.786141.29[-x+1/2, y-1/2, -z+1/2]
O11-H11A···N42.878135.87[x-1/2, -y+1/2, z-1/2]
O10-H10A···O12.615160.38[x, y+1, z ]
Table
Table 3. pH of the media after dissolution.
Table 3. pH of the media after dissolution.
SamplesOriginal SampleApxPhysical MixtureApx–Que–2ACNApx–Que
Pure water76.56.16.26.0
0.1 M HCl1.11.11.11.11.1
ABS4.54.54.54.54.5
PBS6.86.86.86.86.8
Table
Table 4. Pharmacokinetic parameters after oral administration of Apx, physical mixture, and Apx–Que (60 mg/kg) in rats (x ± s, n = 5).
Table 4. Pharmacokinetic parameters after oral administration of Apx, physical mixture, and Apx–Que (60 mg/kg) in rats (x ± s, n = 5).
ParameterApxPhysical MixtureApx–Que
AUC0-t (μg·L−1·h)1164.92 ± 314.64485.77 ± 146.9628,994.69 ± 7555.7
AUC0-∞ (μg·L−1·h)1363.98 ± 316.70677.07 ± 134.6229,173.15 ± 7646.13
MRT0-t (h)6.26 ± 1.84.69 ± 0.646.41 ± 1.22
MRT0-∞ (h)10.33 ± 5.897.36 ± 2.036.54 ± 1.234
t1/2 (h)6.89 ± 4.513.92 ± 2.113.02 ± 0.46
Tmax (h)2.80 ± 1.304.17 ± 1.945.40 ± 1.34
CLz/F (L·h−1·kg−1)46.24 ± 12.2091.22 ± 15.842.19 ± 10.66
Vz/F (L·kg−1)0.428 ± 0.2340.494 ± 0.2390.009 ± 0.004
Cmax (μg·L−1)141.18 ± 47.7895.67 ± 39.144551.72 ± 932.91
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Zhang, L.; Kong, D.; Wang, H.; Jiao, L.; Zhao, X.; Song, J.; Yang, D.; Yang, H.; Yang, S.; Du, G.; et al. Cocrystal of Apixaban–Quercetin: Improving Solubility and Bioavailability of Drug Combination of Two Poorly Soluble Drugs. Molecules 2021, 26, 2677. https://doi.org/10.3390/molecules26092677

AMA Style

Zhang L, Kong D, Wang H, Jiao L, Zhao X, Song J, Yang D, Yang H, Yang S, Du G, et al. Cocrystal of Apixaban–Quercetin: Improving Solubility and Bioavailability of Drug Combination of Two Poorly Soluble Drugs. Molecules. 2021; 26(9):2677. https://doi.org/10.3390/molecules26092677

Chicago/Turabian Style

Zhang, Li, Dewen Kong, Hongjuan Wang, Lingtai Jiao, Xiaoyue Zhao, Junke Song, Dezhi Yang, Haiguang Yang, Shiying Yang, Guanhua Du, and et al. 2021. "Cocrystal of Apixaban–Quercetin: Improving Solubility and Bioavailability of Drug Combination of Two Poorly Soluble Drugs" Molecules 26, no. 9: 2677. https://doi.org/10.3390/molecules26092677

Article Metrics

Back to TopTop